

Supplementary Material

Article Title: Sleep-Associated Adverse Events During the Methylphenidate Treatment of Attention-

Deficit/Hyperactivity Disorder: A Meta-Analysis

Author(s): Stephen V. Faraone, PhD; Michelle D. Po, PhD; Marina Komolova, PhD;

and Samuele Cortese, MD, PhD

DOI Number: https://doi.org/10.4088/JCP.18r12210

List of Supplementary Material for the article

1. Appendix 1 Search Strategy

2. <u>Table 1</u> Study Assessment Methodology

3. <u>Table 2</u> Confounding Variables

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Appendix 1: Search Strategy

The search strategy/syntax for Pubmed.gov was:

((ADHD OR attention deficit OR attention-deficit OR attention deficit hyperactivity disorder OR hyperkinetic syndrome OR hyperkinetic disorder OR hyperactivity disorder OR hyperactive child syndrome) AND (stimulant* OR psychostimulant* OR Methylphenidate OR Aptensio OR Biphentin OR Rubifen OR Focalin OR Methylin OR Cotempla OR Ritalin OR Metadate OR Equasym OR Medikinet OR Concerta OR Daytrana OR Quillivant OR NWP06 OR Quillichew OR HLD200 OR PRC-063) AND (Randomized OR randomised OR random* OR cross-over OR crossover OR parallel OR classroom)) OR ((ADHD OR attention deficit OR attention-deficit OR attention deficit hyperactivity disorder OR hyperkinetic syndrome OR hyperkinetic disorder OR hyperactivity disorder OR hyperactive child syndrome) AND (stimulant* OR psychostimulant* OR Methylphenidate OR Aptensio OR Biphentin OR Rubifen OR Focalin OR Methylin OR Cotempla OR Ritalin OR Metadate OR Equasym OR Medikinet OR Concerta OR Daytrana OR Quillivant OR NWP06 OR Quillichew OR HLD200 OR PRC-063) AND (sleep OR insomnia)).

The search strategy for OVID databases OVID databases (PsycInfo, EMBASE+EMBASE classic, OVID Medline) was:

((ADHD OR attention deficit OR attention-deficit OR attention deficit hyperactivity disorder OR attention-deficit/hyperactivity disorder OR hyperkinetic syndrome OR hyperkinetic disorder OR hyperactivity disorder OR hyperactive child syndrome) AND (stimulant* OR psychostimulant* OR Methylphenidate OR Aptensio OR Biphentin OR Rubifen OR Focalin OR Methylin OR Cotempla OR Ritalin OR Metadate OR Equasym OR Medikinet OR Concerta OR Daytrana OR Quillivant OR NWP06 OR Quillichew OR HLD200 OR PRC-063) AND

(Randomized OR randomised OR random* OR cross-over OR crossover OR parallel OR classroom)) OR ((ADHD OR attention deficit OR attention-deficit OR attention deficit hyperactivity disorder OR attention-deficit/hyperactivity disorder OR hyperkinetic syndrome OR hyperkinetic disorder OR hyperactivity disorder OR hyperactive child syndrome) AND (stimulant* OR psychostimulant* OR Methylphenidate OR Aptensio OR Biphentin OR Rubifen OR Focalin OR Methylin OR Cotempla OR Ritalin OR Metadate OR Equasym OR Medikinet OR Concerta OR Daytrana OR Quillivant OR NWP06 OR Quillichew OR HLD200 OR PRC-063) AND (sleep OR insomnia)).

The search strategies for Web of Knowledge (Web of Science [Science Citation Index Expanded], Biological Abstracts, BIOSIS, Food Science and Technology Abstracts) was:

Search 1: (ADHD OR attention deficit OR attention-deficit OR attention deficit hyperactivity disorder OR hyperkinetic syndrome OR hyperkinetic disorder OR hyperactivity disorder OR hyperactive child syndrome) AND (stimulant* OR psychostimulant* OR Methylphenidate OR Aptensio OR Biphentin OR Rubifen OR Focalin OR Methylin OR Cotempla OR Ritalin OR Metadate OR Equasym OR Medikinet OR Concerta OR Daytrana OR Quillivant OR NWP06 OR Quillichew OR HLD200 OR PRC-063) AND (Randomized OR randomised OR random* OR cross-over OR crossover OR parallel OR classroom).

Search 2: (ADHD OR attention deficit OR attention-deficit OR attention deficit
hyperactivity disorder OR attention-deficit/hyperactivity disorder OR hyperkinetic syndrome
OR hyperkinetic disorder OR hyperactivity disorder OR hyperactive child syndrome) AND
(stimulant* OR psychostimulant* OR Methylphenidate OR Aptensio OR Biphentin OR Rubifen
OR Focalin OR Methylin OR Cotempla OR Ritalin OR Metadate OR Equasym OR Medikinet

OR Concerta OR Daytrana OR Quillivant OR NWP06 OR Quillichew OR HLD200 OR PRC-063) AND (sleep OR insomnia).

The search strategy for ClinicalTrials.gov was: Condition: ADHD; Other terms: methylphenidate OR dexmethylphenidate; Status-> Studies: Completed.

Supplementary Table 1: Study Assessment Methodology

Study	Drug	Rater	Methodology	
Pliszka 2017	DR/ER-MPH	Clinician	Solicited by Direct query – MedDRA version 18.0	
Greenhill 2002	,	Clinician	Spontaneous – COSTART 3 rd edition	
	MPH CD	Parent	Solicited by PSERS	
	MPH CD		·	
Findling 2006	MPH IR	Clinician	Spontaneous – Coding system not specified	
	MPH LA	Parent		
Pearson 2013		Teacher	Solicited by a checklist of sleep items	
Biederman 2003	MPH LA	Clinician	Spontaneous – Coding system not specified	
Simonoff 2013	MPH IR	Parent	Solicited by AE questionnaire	
Lee 2011	MPH IR	Parent	Solicited by SERS	
Dannart 2000	MPH IR	Self-report	Solicited by STESS	
Rapport 2008		Parent	Solicited by STESS	
		Clinician	Spontaneous – Coding system not specified	
Daviss 2008	MPH IR	Parent	Califized by DCEDC	
		Teacher	Solicited by PSERS	
Pelham 1999	MPH IR	Parent	Solicited by PSERS	
Stein 1996	MPH IR	Parent	Solicited by SERS	
Buitelaar 1996	MPH IR	Parent	Solicited by SERS	
Ahman 1993	MPH IR	Parent	Solicited by SERS	
Barkley 1990	MPH IR	Parent	Solicited by SERS	
Barkley 1990	IVIFITIK	Teacher	Solicited by SENS	
Ramtvedt 2014	MPH IR	Parent	Solicited by SERS	
Arnold 2005	MPH IR	Clinician	Spontaneous – COSTART version not specified	
Klorman 1990	MPH IR	Self-report Parent	Solicited by STESS	
FIU 2002	MPH IR	Parent	Solicited by PSERS	
	MPH-IR	Parent	Solicited by SSEC	
Pelham 1990	MPH-SR			
Wigal 2015	MPH MLR	Clinician	Spontaneous – MedDRA version not specified	
Findling 2010	MTS	Clinician	Spontaneous – MedDRA version 7.0	
Wilens 2010	MTS	Clinician	Spontaneous – Coding system not specified	
	MTS OROS MPH		Spontaneous – MedDRA version 7.0	
Findling 2008		Clinician	Solicited by CSHQ	
riliulling 2006			Spontaneous – MedDRA version 7.0	
			Solicited by CSHQ	
Becker 2016	OROS MPH	Parent	Solicited by PSERS	
CHMC 2010	OROS MPH	Parent	Solicited by systematic assessment of AEs	
Coghill 2013	OROS MPH	Clinician	Spontaneous – MedDRA version 11.1	
Stein 2003	OROS MPH	Parent	Solicited by SERS	
Wilens 2006	OROS MPH	Clinician	Spontaneous – Coding system not specified	
Lin 2014	OROS MPH	Clinician	Spontaneous – Coding system not specified	
Newcorn 2008	OROS MPH	Clinician	Spontaneous – MedDRA version 5.1	
Riggs 2012	OROS MPH	Clinician	Spontaneous – Coding system not specified	
Kollins 2016	PRC-063	Clinician	Spontaneous – Coding system not specified	
Childress 2009	d-MPH-ER	Clinician	Spontaneous – MedDRA version not specified	
Greenhill 2006	d-MPH-ER	Clinician	Spontaneous – MedDRA version not specified	
Stein 2011	d-MPH-ER	Parent	Solicited by SERS	

Supplementary Table 2: Confounding Variables								
Variable Relative risk								
- variable	for Sleep AEs	Associat	Association with					
Subject Features	TOT STEEP ALS	Relative Risk	Drug					
		Relative NISK	Diug					
Mean Age 8-8.7	2.5							
	2.5 3.3							
8.8-9.2		0.003	40.0001					
9.3-10.0	2.7	0.003	<0.0001					
10.2-10.9	6.2							
11.0-16.5	3.6							
% Males in Sample	4.4							
64-70	4.1							
72-75	5.5		<0.0001					
76-80	2.9	<0.0001						
81-88	4.1							
89-100	1.8							
Stimulant responder (%)								
0	6.3							
64	2.1	<0.0001	<0.0001					
100	3.6							
Drug Features								
Release type								
Immediate release	1.9	0.03	<0.0001					
Extended release	4.8	0.03	<0.0001					
Dosing frequency								
Once-daily	4.6							
Twice-daily	1.7	<0.0001	<0.0001					
Thrice-daily	2.5	<0.0001	<0.0001					
Missing	1.2							
Study Design Features								
Year								
1990-1999	1.9							
2002-2006	3.3							
2008-2010	3.8	0.03	< 0.0001					
2011-2014	4.8							
2015-2017	4.8							
Method of Diagnosis								
DSM	3.7		a					
Other	2.0	<0.0001	0.58					
Number of Sites								
1	2.5							
2-15	2.6							
16-31	5.3	0.0003	<0.0001					
32-48	5.3	0.0003	·0.0001					
Missing	4.0							
Dosing methods	7.0							
Stabilized & optimized / Not								
forced	4.8	<0.0001	0.05					
Torceu								

Neither stabilized nor optimized / Forced	4.6			
Neither stabilized nor optimized / Not forced	3.0			
Missing	8.5			
Rater of AEs				
Clinician/Investigator	5.3			
Self-reporter	0.9			
Parent	2.5	< 0.0001	< 0.0001	
Teacher	1.6			
Missing	1.3			
Rating scale elicited AEs				
No	5.0	0.02 <0.0001		
Yes	2.3			